Alantolactone Improves Prolonged Exposure of Interleukin-6-Induced Skeletal Muscle Inflammation Associated Glucose Intolerance and Insulin Resistance

The pro-inflammatory cytokine, Interleukin-6 (IL-6), has been proposed to be one of the mediators that link chronic inflammation to glucose intolerance and insulin resistance. Many studies have demonstrated the effects of IL-6 on insulin action in the skeletal muscle. However, few studies have investigated the effect of long-term treatment of IL-6, leading to glucose intolerance and insulin resistance. In the present study, we observed protective effects of alantolactone, a sesquiterpene lactone isolated from Inula helenium against glucose intolerance and insulin resistance induced by prolonged exposure of IL-6. Alantolactone has been reported to have anti-inflammatory and anti-cancer effects through IL-6-induced signal transducer and activator of transcription 3 (STAT3) signaling pathway. The relationship between IL-6 exposure and expression of toll-like receptor 4 (TLR4), involved in inflammation in the skeletal muscle, and the underlying mechanisms were investigated. We observed maximum dysregulation of glucose uptake after 40 ng/ml IL-6 induction for 24 h in L6 myotubes. Prolonged IL-6 exposure suppressed glucose uptake regulating alpha serine/threonine-protein kinase (AKT) phosphorylation; however, pretreatment with alantolactone activated AKT phosphorylation and improved glucose uptake. Alantolactone also attenuated IL-6-stimulated STAT3 phosphorylation, followed by an increase in expression of negative regulator suppressor of cytokine signaling 3 (SOCS3). Furthermore, IL-6-induced expression of pathogen recognition receptor, TLR4, was also suppressed by alantolactone pretreatment. Post-silencing of STAT3 using siRNA approach, IL-6-stimulated siRNA-STAT3 improved glucose uptake and suppressed TLR4 gene expression. Taken together, we propose that, as a STAT3 inhibitor, alantolactone, improves glucose regulation in the skeletal muscle by inhibiting IL-6-induced STAT3-SOCS3 signaling followed by inhibition of the TLR4 gene expression. Therefore, alantolactone can be a promising candidate for the treatment of inflammation-associated glucose intolerance and insulin resistance.

[1]  Yeong Shik Kim,et al.  Alantolactone improves palmitate‐induced glucose intolerance and inflammation in both lean and obese states in vitro: Adipocyte and adipocyte‐macrophage co‐culture system , 2017, International immunopharmacology.

[2]  Li Chen,et al.  Mechanisms Linking Inflammation to Insulin Resistance , 2015, International journal of endocrinology.

[3]  Yeong Shik Kim,et al.  Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. , 2015, Cancer letters.

[4]  J. Zierath,et al.  Constitutive STAT3 Phosphorylation Contributes to Skeletal Muscle Insulin Resistance in Type 2 Diabetes , 2013, Diabetes.

[5]  Ian A. Trounce,et al.  Deletion of Skeletal Muscle SOCS3 Prevents Insulin Resistance in Obesity , 2012, Diabetes.

[6]  Youn-Chul Kim,et al.  Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. , 2012, International immunopharmacology.

[7]  R. Goyal,et al.  Evaluation of TNF-α and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects , 2012, North American journal of medical sciences.

[8]  Yup Kang,et al.  IL-6 induction of TLR-4 gene expression via STAT3 has an effect on insulin resistance in human skeletal muscle , 2013, Acta Diabetologica.

[9]  A. C. Könner,et al.  Toll-like receptors: linking inflammation to metabolism , 2011, Trends in Endocrinology & Metabolism.

[10]  Dorothy D. Sears,et al.  TLR4 and Insulin Resistance , 2010, Gastroenterology Research and Practice.

[11]  B. Faubert,et al.  Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK. , 2010, Biochemical and biophysical research communications.

[12]  M. Lorenzo,et al.  Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal Muscle , 2008, Diabetes.

[13]  E. Tsiani,et al.  Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. , 2008, Biochemical and biophysical research communications.

[14]  R. DeFronzo,et al.  Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects , 2008, Diabetes.

[15]  Hui-yu Liu,et al.  Regulation of Interleukin-6-induced Hepatic Insulin Resistance by Mammalian Target of Rapamycin through the STAT3-SOCS3 Pathway* , 2008, Journal of Biological Chemistry.

[16]  B. Kemp,et al.  The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  R. Mooney,et al.  Interleukin-6 depletion selectively improves hepatic insulin action in obesity. , 2005, Endocrinology.

[18]  C. Kahn,et al.  Suppressor of Cytokine Signaling 1 (SOCS-1) and SOCS-3 Cause Insulin Resistance through Inhibition of Tyrosine Phosphorylation of Insulin Receptor Substrate Proteins by Discrete Mechanisms , 2004, Molecular and Cellular Biology.

[19]  T. Zimmers,et al.  Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes* , 2003, The Journal of Biological Chemistry.

[20]  D. Finn,et al.  mechanisms linking , 2022 .